a meaningful CFU count (1015 billion or more)
Tirzepatide came off the FDAs official drug shortage list in December 2024, and semaglutide followed in February 2025, eliminating the legal pathway that allowed compounding pharmacies to produce copies of the drugs
Most patients who achieve their target weight continue taking semaglutide for at least 1224 months, though many stay on therapy longer
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that effectively controls blood glucose and promotes weight loss, but discontinuation often leads to weight regain and glycemic deterioration
However, regular injections are recommended for ongoing benefits
Beyond the Skin: Other Benefits of GHK-Cu While GHK-Cu has certainly earned its reputation as a skincare powerhouse, its benefits don't stop at the surface